Endoscopy solutions offer more visualization, access, and flexibility; providers achieve more efficiency, designed to improve outcomes

LEXINGTON, Mass., May 15, 2019 (Booth #4823) – Fujifilm will showcase its portfolio of endoscopic imaging, minimally invasive surgical endoscopy, enterprise imaging, and hepatology surveillance solutions at Digestive Disease Week® (DDW) 2019 from May 19-21 at the San Diego Convention Center in San Diego, CA. Fujifilm products will also be included in more than a dozen educational and training opportunities during the conference.

“In today’s competitive climate, endoscopists and gastroenterologists are often expected to achieve more with less staff, less budget and less time,” said Taisuke Fujita, General Manager of FUJIFILM Medical Systems U.S.A., Inc. “Fujifilm’s unique combination of video platforms and endoscopes allow for multiple visualizations as well as more flexibility and more control, so busy clinicians can achieve more efficiencies during procedures and improve patient outcomes.”

Technology that Empowers Clinicians to See More, Control More

In booth #4823 at DDW 2019, Fujifilm will showcase the following endoscope solutions for ERCP, EUS, Colonoscopy, and Gastroscopy including hands on ESD, EUS and ERCP activities in tissue models:

ELUXEO Endoscopic Visualization System: ELUXEO, comprised of Fujifilm’s 7000 Video Imaging System and 700 Series Endoscopes, features 4-LED Multi-Light Technology, which creates Blue Light Imaging (BLI) and Linked Color Imaging (LCI®) special light observation modes. This platform offers exceptional image quality in terms of sharpness and brightness, delivering optimal visual information for diagnostic and therapeutic procedures in daily clinical practice.

Endoscopic Submucosal Dissection (ESD): These devices are designed for use with compatible endoscopes to aid clinicians in performing effective ESD interventions within the digestive tract. ClutchCutter® is a rotatable forceps, FlushKnife a versatile and efficient diathermic slitter, and ST Hood Short Type is intended to maintain field of view during endoscopic procedures such as mucosal resection.

Interventional scopes for ERCP: Fujifilm’s new ED-580XT Duodenoscope combines optimal visual orientation with exceptional maneuverability and control, helping to achieve cannulation efficiently. It has a removable single use distal end cap, facilitating access behind the elevator, designed to allow a more thorough manual cleaning. The EI-580BT* Short Double Balloon enables ERCP access in surgically altered anatomy patients.

Interventional scopes for EUS: Fujifilm’s ultrasonic video endoscopes coupled with the Sonart SU-1 ultrasonic processor, provide visualization of surrounding structures, allowing clinicians to see beyond the pathway and support diagnosis and determine treatment. At DDW, Fujifilm will debut its new EG-580UT Ultrasonic Endoscope* which features precise needle trajectory when targeting lesions for FNA.

Full High Definition Surgical Visualization System—Designed for a wide variety of surgical applications, this solution includes a portfolio of rigid surgical scopes, cameras and video processing systems. The camera includes optimized settings for various clinical specialties. The system’s Full HD Video Controller offers edge enhancement, automatic gain control (AGC) and dynamic contrast function. In addition, selective color enhancement, smoke reduction, and grid removal features each enhance observation abilities. A High Power 200 LED Light Source allows the user to adjust the intensity of the light from 5-100%—providing operational efficiency and lowering power consumption.

Hepatocellular Carcinoma (HCC) Surveillance— FUJIFILM Wako Diagnostics U.S.A. Corporation’s HCC risk biomarkers AFP-L3 and DCP are intended for in vitro diagnostic use, designed to aid in the risk assessment of patients with chronic liver disease. As early detection of HCC is crucial for the application of curative therapies and improving patient outcomes, HCC surveillance is a widely recommended practice. Adding the two biomarkers, AFP-L3 and DCP, to HCC surveillance practice can increase the chances of detecting early HCC.

Synapse VNA— The core of a comprehensive enterprise-imaging strategy involves a vendor neutral archive (VNA), and Fujifilm TeraMedica’s Synapse VNA leads the market.  The Synapse VNA securely captures, stores, and manages all clinical images and content across 30+ specialty departments while providing interoperability throughout the enterprise to create a complete picture of patient health.  With Synapse VNA, healthcare organizations can achieve cost savings, improve clinical outcomes, and optimize workflow efficiencies.

For more information on Fujifilm’s offerings at DDW, including a list of products available to demo, please visit http://www.fujifilmddw.com

*Not commercially available in the U.S

About Fujifilm

FUJIFILM Medical Systems U.S.A., Inc. is a leading provider of diagnostic imaging products and medical informatics solutions that meet the evolving needs of healthcare facilities both today and tomorrow. From an unrivaled selection of digital X-ray systems, to the comprehensive Synapse® Enterprise Imaging portfolio, to full-field digital mammography systems with digital breast tomosynthesis, and computed tomography solutions for oncology and radiology applications, Fujifilm has products that are ideal for any size imaging environment. FUJIFILM Medical Systems U.S.A., Inc. – Endoscopy supplies high quality, technologically advanced endoscopic imaging solutions and devices to the medical field. Fujifilm’s TeraMedica Division, the leading provider of vendor neutral, enterprise-wide solutions for unrestricted medical image management and the core to the Synapse Enterprise Imaging portfolio, enables improved patient care by connecting imaging content across the entire care continuum. FUJIFILM Medical Systems U.S.A., Inc. is headquartered in Lexington, Massachusetts. For more information please visit www.fujimed.com and www.fujifilmendoscopy.com.

FUJIFILM New Development, U.S.A., Inc., is an innovative provider of minimally invasive surgical systems designed to meet the needs of surgeons across the clinical spectrum today and well into the future. From an unparalleled ultra-slim video laparoscope system to a full high definition surgical visualization system, Fujifilm’s product portfolio is revolutionizing the conventional surgical endoscopic procedure and raising the standard of patient care.

FUJIFILM Holdings Corporation in Tokyo, Japan, brings innovative solutions to a broad range of global industries by leveraging its depth of knowledge and fundamental technologies derived from photographic film. Its proprietary core technologies contribute to the fields of healthcare, graphic systems, highly functional materials, optical devices, digital imaging and document products. These products and services are based on its extensive portfolio of chemical, mechanical, optical, electronic and imaging technologies. For the year ended March 31, 2018, the company had global revenues of $23.0 billion, at an exchange rate of 106 yen to the dollar. Fujifilm is committed to responsible environmental stewardship and good corporate citizenship. For more information, please visit: www.fujifilmholdings.com.




Danielle Brown